No Data
No Data
This Analyst Sees Potential Downside In Eli Lilly, Adjusts Model For Acquired IPR&D Charges
Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating on the shares of Eli Lilly And Co (NYSE:LLY) and maintained a price target of $885.The company is slated to report its second-
Akero Therapeutics(AKRO.US) Officer Sells US$117.02K in Common Stock
$Akero Therapeutics(AKRO.US)$ Officer Young Jonathan sold 5,000 shares of common stock on Jul 1, 2024 at an average price of $23.404 for a total value of $117.02K.Source: Announcement What is statemen
Form 144 | Akero Therapeutics(AKRO.US) Officer Proposes to Sell 351.9K in Common Stocks
SEC FILLINGS DISCLOSED/ Jul 1, $Akero Therapeutics(AKRO.US)$ Officer Jonathan Young intends to sell 15,000 shares of its common stock on Jul 1, with a total market value of approximately $351.9K. Jo
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Akero Therapeutics
Faruqi & Faruqi Logo (PRNewsfoto/Faruqi & Faruqi, LLP)
Express News | Cantor Fitzgerald Reiterates Overweight on Akero Therapeutics
CCORF Maintains Akero Therapeutics(AKRO.US) With Buy Rating, Maintains Target Price $56
CCORF analyst Edward Nash maintains $Akero Therapeutics(AKRO.US)$ with a buy rating, and maintains the target price at $56.According to TipRanks data, the analyst has a success rate of 40.9% and a tot